Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of combination low dose rate brachytherapy (LDR) added to standard of
care (SOC) immunotherapy with Nivolumab in stage III and IV melanoma.